July 24, 2025

Durable Molecular Remission in TCF3::HLF-Positive Pediatric B-ALL Using Post-Transplant Azacitidine, DLI and Blinatumomab

View Full Paper

Ask AI

Bookmark

Authors

XGXuemei GuoSecond Affiliated Hospital of Nanjing Medical University YWYongren WangNanjing Children's Hospital LRLiucheng RongNanjing Children's Hospital

Discussion

Member takes

Implication

Case presentation demonstrates sustained molecular remission in a child with TCF3::HLF-positive B-ALL, highlighting azacitidine and DLI's role alongside blinatumomab.

Key Points

The case shows that a combination therapy can lead to durable molecular remission in TCF3::HLF-positive B-ALL.
The treatment regimen included azacitidine, DLI, and blinatumomab, achieving MRD levels below 0.01%.
Molecular relapse occurred despite initial MRD negativity, indicating the aggressive nature of this leukemia.
Results support the need for novel therapies in high-risk B-ALL subtypes after hematopoietic stem cell transplantation.

Cite This Study

Guo et al. (2025) studied this question.

synapsesocial.com/papers/689a0627e6551bb0af8cdf23 https://doi.org/10.21203/rs.3.rs-7153539/v1

View Full Paper

Ask AI

Bookmark

Implication

Case presentation demonstrates sustained molecular remission in a child with TCF3::HLF-positive B-ALL, highlighting azacitidine and DLI's role alongside blinatumomab.

Durable Molecular Remission in TCF3::HLF-Positive Pediatric B-ALL Using Post-Transplant Azacitidine, DLI and Blinatumomab

Discussion

Member takes

Implication

Key Points

Cite This Study

Durable Molecular Remission in TCF3::HLF-Positive Pediatric B-ALL Using Post-Transplant Azacitidine, DLI and Blinatumomab

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider